Literature DB >> 8898952

Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13.

N Bessis1, M C Boissier, P Ferrara, T Blankenstein, D Fradelizi, C Fournier.   

Abstract

The anti-inflammatory effects of the recently identified cytokine interleukin (IL)-13 on collagen-induced arthritis (CIA) was explored and compared to those of IL-4 using systemic administration of these cytokines via two injections of xenogeneic vector cells transfected with a plasmid construct. CIA was induced in DBA/I mice by immunization with native bovine type II collagen (CII). Chinese hamster ovary (CHO) fibroblasts transfected with the mouse IL-13 or IL-4 genes were inoculated subcutaneously on days 10 and 25 post-priming with CII and mice were monitored for signs of arthritis by observers unaware of the status of the animal. Incidence and severity of CIA were significantly reduced in the groups of mice treated with IL-13 and IL-4 gene-transfected CHO cells compared to control groups receiving nontransfected cells. Expression of various cytokines in spleen cells from individual mice was assessed by quantitative reverse transcriptase-polymerase chain reaction at different times after immunization. Our data show that IL-13-induced suppression of CIA coincided with a decreased TNF-alpha mRNA expression in the spleen of treated animals. This may explain at least partially the anti-inflammatory effects of IL-13 in CIA. Thus, our results may have important implications for the clinical use of T helper (Th)1/TH2 modulatory cytokines as therapeutic agents in the treatment of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8898952     DOI: 10.1002/eji.1830261020

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  38 in total

1.  Gene therapy in the treatment of autoimmune diseases.

Authors:  G C Tsokos; G T Nepom
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis.

Authors:  Y Morita; J Yang; R Gupta; K Shimizu; E A Shelden; J Endres; J J Mulé; K T McDonagh; D A Fox
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Interleukin-4 cellular gene therapy and osteoprotegerin decrease inflammation-associated bone resorption in collagen-induced arthritis.

Authors:  Nathalie Saidenberg-Kermanac'h; Natacha Bessis; Delphine Lemeiter; Marie-Christine de Vernejoul; Marie-Christophe Boissier; Martine Cohen-Solal
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

4.  The Th1-Th2 model--what relevance to inflammatory arthritis?

Authors:  P D Kiely
Journal:  Ann Rheum Dis       Date:  1998-06       Impact factor: 19.103

Review 5.  Cytokine therapy in rheumatoid arthritis.

Authors:  J Hermann; M Walmsley; F M Brennan
Journal:  Springer Semin Immunopathol       Date:  1998

Review 6.  Gene therapy for rheumatoid arthritis.

Authors:  P D Robbins; C H Evans; Y Chernajovsky
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Will the increasing prevalence of atopy have a favourable impact on rheumatoid arthritis?

Authors:  J S Gaston
Journal:  Ann Rheum Dis       Date:  1998-05       Impact factor: 19.103

Review 8.  Gene therapy for rheumatoid arthritis. Theoretical considerations.

Authors:  Y Chernajovsky; A Annenkov; C Herman; K Triantaphyllopoulos; D Gould; H Dreja; S P Moyes; J L Croxford; R A Mageed; O L Podhajcer; D Baker
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 9.  A gene therapy approach to treatment of autoimmune disease.

Authors:  C M Seroogy; C G Fathman
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

10.  A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia.

Authors:  P Larsson; L Mattsson; L Klareskog; C Johnsson
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.